A new model to study the spread of deadly colorectal and gastric cancers.
Official title: A vascularized microphysiological system (MPS) platform for modeling peritoneal carcinomatosis
Funded at University of California-Irvine · NIH-11094078 · Data updated 2026-11-12
This study is creating a special lab model to learn more about how cancer spreads in the abdomen, which could help improve treatments for patients with colorectal and gastric cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $521,240 |
| NIH project number | 5R01CA290115-02 |
| Project ID | NIH-11094078 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with colorectal or gastric cancer, particularly those experiencing peritoneal carcinomatosis.
✕Less likely to help
Patients with early-stage colorectal or gastric cancer without metastasis may not benefit from this research.
What this research studies
This research focuses on developing a sophisticated laboratory model to better understand peritoneal carcinomatosis, a severe form of cancer spread from colorectal and gastric tumors. By utilizing a vascularized microphysiological system, researchers will observe how cancer cells behave in a 3D environment that mimics the human body. This approach aims to fill the gaps in current knowledge about cancer metastasis and improve the development of effective therapies. Patients may benefit from advancements in treatment options that arise from this innovative model.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients suffering from peritoneal carcinomatosis.
How similar studies have gone: Previous research using similar microphysiological systems has shown promise in understanding cancer biology and developing new treatments.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Hughes, Christopher C. W. — University of California-Irvine
- Study coordinator: Hughes, Christopher C. W.
Related research
Other NIH-funded projects on the same topics.
-
Repeated PIPAC plus standard platinum–taxane chemotherapy for advanced ovarian cancer with peritoneal spread
This test sees if adding repeated cisplatin-based PIPAC to standard platinum–taxane chemotherapy helps women aged 18–75 with newly diagnosed FIGO IIIB–IIIC epithelial ovarian cancer and visible peritoneal carcinomatosis.
-
Enhanced Recovery After Surgery for adults with peritoneal carcinomatosis undergoing cytoreductive surgery with or without HIPEC
This project will try an Enhanced Recovery After Surgery (ERAS) program to see if it shortens hospital stays after cytoreductive surgery with or without HIPEC for adults with peritoneal carcinomatosis.
-
PIPAC with Mitomycin C for unresectable peritoneal cancer
This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.
-
Heated versus aerosolized chemotherapy delivered into the abdomen for cancer that has spread to the peritoneum
This study will test whether heated (HIPEC) or aerosolized (PIPAC) mitomycin-based chemotherapy given into the abdomen works better and is safer for adults whose cancer has spread to the peritoneum.
-
Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum
This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.
-
Blood clearance of nucleosomes and CTCF after surgery for colorectal cancer with peritoneal spread
This test will see if blood levels of nucleosomes and CTCF can indicate whether adults with colorectal cancer that has spread to the peritoneum have had all visible tumor removed by cytoreductive surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.